NYLIM
IGMS

New York Life Investment Management’s IGM Biosciences IGMS Stock Holding History

New York Life Investment Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-21,167
Closed -$360K – 1289
2022
Q4 		$360K Buy
21,167
+2,337
+12% +$46.7K ﹤0.01% 1083
2022
Q3 		$428K Buy
18,830
+1,384
+8% +$27.9K 0.01% 880
2022
Q2 		$315K Buy
+17,446
New +$311K ﹤0.01% 1137

Other funds holding IGMS

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

New York Life Investment Management's IGMS Position: Q1 2023 in Review

New York Life Investment Management sold out of IGM Biosciences (IGMS) in Q1 2023, closing a stake of 21,167 shares — an estimated $360K sold.

New York Life Investment Management first reported a position in IGMS in Q2 2022 and held it in 3 quarters. The position peaked at $428K in Q3 2022. 74 funds tracked by Wall St. Rank hold IGMS as of Q1 2023.

  • New York Life Investment Management reported no remaining IGM Biosciences position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 21,167 IGM Biosciences shares in Q1 2023, an estimated $360K.
  • New York Life Investment Management first reported a position in IGM Biosciences in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's IGM Biosciences position peaked at $428K in Q3 2022.
  • 74 funds tracked by Wall St. Rank held IGM Biosciences as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.